Vifor Pharma, Cara Therapeutics to commercialise kidney disease drug Korsuva in US
Vifor Pharma has entered into a licence agreement with Cara Therapeutics to commercialise Korsuva (difelikefalin) to treat chronic kidney disease-associated pruritus (CKD-aP) in the US.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.